What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
Sell
41
MRUS Quote, Financials, Valuation and Earnings
Last price:
$40.93
Seasonality move
:
4.65%
Day range:
$39.88 - $43.58
52-week range:
$33.19 - $61.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
76.00x
P/B ratio:
4.56x
Volume:
1.5M
Avg. volume:
885.7K
1-year change:
-9.17%
Market cap:
$3B
Revenue:
$36.1M
EPS (TTM):
-$3.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$7.4M | -$1.06 | 2.89% | -74.43% | $84.07 |
|
ARGX
argenx SE
|
$840M | $2.33 | 90.68% | 537.48% | $768.62 |
|
PHAR
Pharming Group
|
$64.1M | -$0.03 | 15.36% | -86.84% | $30.33 |
|
PHVS
Pharvaris NV
|
-- | -$0.94 | -- | -55.88% | $34.36 |
|
PRQR
ProQR Therapeutics NV
|
$5M | -$0.10 | 1.34% | -63.67% | $9.63 |
|
QURE
uniQure NV
|
$6.7M | -$1.06 | -27.53% | -27.05% | $35.51 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$42.77 | $84.07 | $3B | -- | $0.00 | 0% | 76.00x |
|
ARGX
argenx SE
|
$569.12 | $768.62 | $34.8B | 44.78x | $0.00 | 0% | 16.32x |
|
PHAR
Pharming Group
|
$10.01 | $30.33 | $684.6M | -- | $0.00 | 0% | 2.72x |
|
PHVS
Pharvaris NV
|
$17.04 | $34.36 | $928.6M | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$1.55 | $9.63 | $163.1M | -- | $0.00 | 0% | 6.53x |
|
QURE
uniQure NV
|
$12.25 | $35.51 | $662.4M | -- | $0.00 | 0% | 21.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MRUS
Merus NV
|
-- | 0.677 | -- | 6.22x |
|
ARGX
argenx SE
|
-- | 0.824 | -- | 6.40x |
|
PHAR
Pharming Group
|
27.08% | -2.346 | 12.07% | 3.02x |
|
PHVS
Pharvaris NV
|
-- | -1.496 | -- | -- |
|
PRQR
ProQR Therapeutics NV
|
4.92% | 1.018 | 1.71% | 3.89x |
|
QURE
uniQure NV
|
115.15% | -5.041 | 5.93% | 9.32x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MRUS
Merus NV
|
-- | -$88.7M | -38.4% | -38.4% | -969.93% | -$66.7M |
|
ARGX
argenx SE
|
$665.8M | $101.6M | 18.03% | 21.33% | 11.81% | -$147M |
|
PHAR
Pharming Group
|
$80.5M | $6.6M | -3.37% | -5.03% | 9.86% | $9.2M |
|
PHVS
Pharvaris NV
|
-- | -$41.7M | -- | -- | -- | -$38.1M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$10.7M | -57.21% | -62.97% | -150.73% | -$9.8M |
|
QURE
uniQure NV
|
$4.6M | -$42.5M | -131.71% | -239.27% | -1101.88% | -$52.9M |
Merus NV vs. Competitors
-
Which has Higher Returns MRUS or ARGX?
argenx SE has a net margin of -338.33% compared to Merus NV's net margin of 15.95%. Merus NV's return on equity of -38.4% beat argenx SE's return on equity of 21.33%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$0.41 $647.9M ARGXargenx SE90.16% $11.87 $5.5B -
What do Analysts Say About MRUS or ARGX?
Merus NV has a consensus price target of $84.07, signalling upside risk potential of 96.56%. On the other hand argenx SE has an analysts' consensus of $768.62 which suggests that it could grow by 35.23%. Given that Merus NV has higher upside potential than argenx SE, analysts believe Merus NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 ARGXargenx SE13 2 0 -
Is MRUS or ARGX More Risky?
Merus NV has a beta of 0.946, which suggesting that the stock is 5.436% less volatile than S&P 500. In comparison argenx SE has a beta of 0.573, suggesting its less volatile than the S&P 500 by 42.672%.
-
Which is a Better Dividend Stock MRUS or ARGX?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or ARGX?
Merus NV quarterly revenues are $9.1M, which are smaller than argenx SE quarterly revenues of $738.4M. Merus NV's net income of -$30.9M is lower than argenx SE's net income of $774.2M. Notably, Merus NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 44.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 76.00x versus 16.32x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV76.00x -- $9.1M -$30.9M ARGXargenx SE16.32x 44.78x $738.4M $774.2M
-
Which has Higher Returns MRUS or PHAR?
Pharming Group has a net margin of -338.33% compared to Merus NV's net margin of 3.99%. Merus NV's return on equity of -38.4% beat Pharming Group's return on equity of -5.03%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$0.41 $647.9M PHARPharming Group86.82% $0.06 $304.3M -
What do Analysts Say About MRUS or PHAR?
Merus NV has a consensus price target of $84.07, signalling upside risk potential of 96.56%. On the other hand Pharming Group has an analysts' consensus of $30.33 which suggests that it could grow by 203.03%. Given that Pharming Group has higher upside potential than Merus NV, analysts believe Pharming Group is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 PHARPharming Group2 0 0 -
Is MRUS or PHAR More Risky?
Merus NV has a beta of 0.946, which suggesting that the stock is 5.436% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MRUS or PHAR?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PHAR?
Merus NV quarterly revenues are $9.1M, which are smaller than Pharming Group quarterly revenues of $92.7M. Merus NV's net income of -$30.9M is lower than Pharming Group's net income of $3.7M. Notably, Merus NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 76.00x versus 2.72x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV76.00x -- $9.1M -$30.9M PHARPharming Group2.72x -- $92.7M $3.7M
-
Which has Higher Returns MRUS or PHVS?
Pharvaris NV has a net margin of -338.33% compared to Merus NV's net margin of --. Merus NV's return on equity of -38.4% beat Pharvaris NV's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$0.41 $647.9M PHVSPharvaris NV-- -$0.85 -- -
What do Analysts Say About MRUS or PHVS?
Merus NV has a consensus price target of $84.07, signalling upside risk potential of 96.56%. On the other hand Pharvaris NV has an analysts' consensus of $34.36 which suggests that it could grow by 101.63%. Given that Pharvaris NV has higher upside potential than Merus NV, analysts believe Pharvaris NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 PHVSPharvaris NV6 0 0 -
Is MRUS or PHVS More Risky?
Merus NV has a beta of 0.946, which suggesting that the stock is 5.436% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MRUS or PHVS?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PHVS?
Merus NV quarterly revenues are $9.1M, which are larger than Pharvaris NV quarterly revenues of --. Merus NV's net income of -$30.9M is higher than Pharvaris NV's net income of -$45.9M. Notably, Merus NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 76.00x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV76.00x -- $9.1M -$30.9M PHVSPharvaris NV-- -- -- -$45.9M
-
Which has Higher Returns MRUS or PRQR?
ProQR Therapeutics NV has a net margin of -338.33% compared to Merus NV's net margin of -216.04%. Merus NV's return on equity of -38.4% beat ProQR Therapeutics NV's return on equity of -62.97%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$0.41 $647.9M PRQRProQR Therapeutics NV-- -$0.10 $96.9M -
What do Analysts Say About MRUS or PRQR?
Merus NV has a consensus price target of $84.07, signalling upside risk potential of 96.56%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $9.63 which suggests that it could grow by 520.97%. Given that ProQR Therapeutics NV has higher upside potential than Merus NV, analysts believe ProQR Therapeutics NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 PRQRProQR Therapeutics NV6 0 0 -
Is MRUS or PRQR More Risky?
Merus NV has a beta of 0.946, which suggesting that the stock is 5.436% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.356, suggesting its less volatile than the S&P 500 by 64.408%.
-
Which is a Better Dividend Stock MRUS or PRQR?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PRQR?
Merus NV quarterly revenues are $9.1M, which are larger than ProQR Therapeutics NV quarterly revenues of $4.6M. Merus NV's net income of -$30.9M is lower than ProQR Therapeutics NV's net income of -$9.9M. Notably, Merus NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 76.00x versus 6.53x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV76.00x -- $9.1M -$30.9M PRQRProQR Therapeutics NV6.53x -- $4.6M -$9.9M
-
Which has Higher Returns MRUS or QURE?
uniQure NV has a net margin of -338.33% compared to Merus NV's net margin of -1403.2%. Merus NV's return on equity of -38.4% beat uniQure NV's return on equity of -239.27%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$0.41 $647.9M QUREuniQure NV88.14% -$1.50 $44.6M -
What do Analysts Say About MRUS or QURE?
Merus NV has a consensus price target of $84.07, signalling upside risk potential of 96.56%. On the other hand uniQure NV has an analysts' consensus of $35.51 which suggests that it could grow by 190.85%. Given that uniQure NV has higher upside potential than Merus NV, analysts believe uniQure NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV13 0 0 QUREuniQure NV9 2 0 -
Is MRUS or QURE More Risky?
Merus NV has a beta of 0.946, which suggesting that the stock is 5.436% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.099, suggesting its less volatile than the S&P 500 by 90.134%.
-
Which is a Better Dividend Stock MRUS or QURE?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or QURE?
Merus NV quarterly revenues are $9.1M, which are larger than uniQure NV quarterly revenues of $5.2M. Merus NV's net income of -$30.9M is higher than uniQure NV's net income of -$73.3M. Notably, Merus NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 76.00x versus 21.98x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV76.00x -- $9.1M -$30.9M QUREuniQure NV21.98x -- $5.2M -$73.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
99
DAVE alert for May 9
Dave [DAVE] is up 9.31% over the past day.
Buy
52
QDEL alert for May 9
QuidelOrtho [QDEL] is down 0.22% over the past day.
Buy
61
TPC alert for May 9
Tutor Perini [TPC] is up 9.61% over the past day.
